کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
1912918 1047198 2012 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)
موضوعات مرتبط
علوم زیستی و بیوفناوری بیوشیمی، ژنتیک و زیست شناسی مولکولی سالمندی
پیش نمایش صفحه اول مقاله
Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)
چکیده انگلیسی

ObjectiveThe purpose of this study was to assess the impact of aging, comorbidities and symptoms on physical function in patients surviving 20 years since adjuvant treatment for breast cancer.Patients and methodsPatients were originally treated on CALGB 7581 (from 1975 to 1980), a randomized trial of three adjuvant therapies and reassessed (153 of 193 eligible survivors) 20 years from the onset of therapy for physical function and symptoms by the EORTC QLQ-C30 and comorbidities by the OARS questionnaire.ResultsThe average age at reassessment was 64.5 years. 66% of patients had at least two comorbidities and 22% had four or more, but relatively little interference with activities. Older patients had greater multimorbidity. Physical function was generally high and comparable to matched population norms. Older patients had greater difficulty with strenuous activities. For every increase in number of comorbidities, physical function score decreased by 5.1 (p < .001). Symptoms were also frequent (80%) and correlated strongly with decreases in function (0–100 u scale) (p < .001), to an even greater degree than comorbidities.ConclusionVery long-term cancer survivors have changes in physical function and symptoms largely consistent with their aging suggesting that the impact of cancer and its treatment is attenuated over time and largely replaced by the impact of age-related comorbidities and functional decline.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of Geriatric Oncology - Volume 3, Issue 2, April 2012, Pages 82–89
نویسندگان
, , , ,